Special Report: Preparing for Stage 1 of the FDA’s LDTs Final Rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
Considerations for addressing compliance with Stage 1 of the FDA’s lab-developed tests final rule
From - Lab Compliance Advisor
Myth: Risk of federal prosecution for health fraud and abuse applies only when you deal with…
From - Lab Compliance Advisor
After a recent dip, OIG enforcement activity has seemingly rebounded, at least in terms of total recoveries. That's the…
From - Lab Compliance Advisor
A new law passed to deal with the opioid epidemic has significant ramifications for labs including but not limited to those involved in drug addiction and…
From - Lab Compliance Advisor
PAMA reporting is tricky business in which mistakes and omissions carry the risk of civil monetary penalties of up to $10,000 per day. So, whether you're with…
From - Lab Compliance Advisor
January is the season when employers must compile their OSHA logs for the previous year. The good news is that many labs are…
From - Lab Compliance Advisor
PAMA's deep Medicare reimbursement cuts have had a devastating impact on the lab industry. Recent CMS changes in the 2019 Final Rule should…